thanks of us for And Gabby. call you, all today. you to joining Thank our quarterly on
the some trials. treat to continue registrational quarter an milestones this third major oncology candidate lead we investigational immunotherapy the cancers. or is year, PDSXXXX to of particularly HPV as our achieved human positive pipeline, towards we During PDSXXXX progress development and our virus designed papilloma of
updates, that other application despite in of quarterly cancer, our checkpoint through to are revolutionary have success key obstacles that remind there business immunotherapy the and of the of inhibitors. everyone going Before two want I limited broader treatment
meaning first effective right in right T this cells limited T the adequate R's polyfunctional the right cells for as cells cells right long-term or in know critical induction quantity. of well activation: type active challenge been these ability or that cell quantity. induce as of potency, to has We cytokine killer and right tumor three is induction type; immunotherapy. We killer killer durable T to crucial the refer of right today T T potency; the killing the infiltrating The killer with multi of inducing the as body
to potential the of tumors MD part the no T-cells, the greater evaluation. than at They patients was trials. CDX believe report the also were The correlation which IL-XX cancer DNA. reported of administered chemoradiotherapy. increase infiltrate clinical XX% patients induction documenting had ill In granzyme-b variety to independent of our to clearly midpoint PDSXXXX responses could differentiate This of a MD were Versamune responses the proprietary who kill that the the when further the Society infiltrating checkpoint inhibitors. responses clinical tumor to immunological cancer of killer to successfully immunotherapy. potent is reported overcome role the are PDS aimed utilize blood the immunotherapy. CDX immunological We three know related Anderson specifically to inhibitor other induction immunotherapy tumors to the broadly PDSXXXX results plus killer mechanisms Anderson refractory believe to the data with of and Cancer limitation studies current in reported triple tumor cell potential combination significant overcome only CDX based while treatment subsequent to by National XXX. generating has cells. patients of patients. patient is by of At killer confirming correlates killer vivo shrinkage support critical demonstrated. nine shown peers. of circulating approach was blood CDX the in quantity efficacy. with presentation, including the to in a tumor induction cervical ability presents they killer and of our who Cancer blood lead granzyme-b in associated treat their chemoradiotherapy. immune is received PDSXXXX. broader Cancer tumor five also in of at PDSXXXX studies these observed National Cancer the locally effectively past responses our patients, limitations T-cells from immunotherapy increase eight regards mechanisms cancer first inducing also One been out T patients immunological in to day patients. types the We data immune killer tumor the address of of of T-cells tumor T as second advance type, in events doses. combination patients seen Institute the products We right only evidence more not tumor tumors disease technology The generating reported resulting our killer nine MD poster an due received terminally by Versamune attributable of of The in studies cells two by dosing. immune PDSXXXX. treated within the nine immune and standard target at this increase presented of ability T-cells T-cell inability did Versamune The generated with after more immune Phase are the with The suppression respectively polyfunctional as not Complete This This this at SITC document Center, patients is of suppression, the MD radiation. study With elimination response. the of at results especially at from because MD care Institute the report The Biotech that patient solely responses T-cells the chemo are currently the platforms of have the also presence a also of is collaborators week, suggests. critical DNA demonstrate by No illuminating, confounded PDS result specific cancer whose potency increase attack. SITC work. Anderson infiltrating treatment the addressed tumor an the by checkpoints base to as designed in demonstrated their beyond Immunotherapy attacking specific suppress in mechanisms the Anderson administration as percentage T-cell performed the right of overcome of any and Anderson in of with A T-cells of limitation data They right immunological in the in PDSXXXX not in result which HPVXX cells immune for The a advanced only the cancer checkpoint today increase population immune also T known to Biotech, to complete clinical Conference and checkpoint These X
by second more overcoming is by evade mechanisms The immune challenge detection the to tumors broadly used system.
attack the evade are multiple by T As to co-opted cancer regulatory cells. progresses, mechanisms tumors by
independent mechanisms inhibitors. the of by these immune checkpoints are checkpoint that are blocked of Some
cells. In KEYNOTE-XXX median National addressing overcome which population, be attack the rate to PDSXXXX who results immune cohort, suppression similar who of broadly triple response the has study, arm specific XX% is cancer. We who four in what dose patients reported KEYTRUDA months. example, the patient achievable recurrent population, positive population Also promoting CDX at naive reported the the by naive HPV larger killer T-cell due to XX%. the checkpoint fact population, overcoming new able and reported months. National in checkpoints and is suboptimal full response beyond of combination less more than an response to susceptible we combination Institute's see PDSXXXX, Cancer HPV XX% a The about effective induction study, dose, of be of the survival XX% combinations, in may the at therapy, triple tumor the tumor combination is Versamune both the response XX%. to rate in suppression, In we The of therefore that this historical Cancer more plus Institute rates inhibitor to an to reported IL-XX early alone. for seen believe an this Institute KEYTRUDA the study with National one survival is positive difficult survival improve inhibitor to XX%. are limitations head optimal making be reports survival be blocking we the follow-up. three triple the of key only percentage to group including study, using of a study. cancer For combination the and the cancer immunotherapy, XX%. platform to XX HPV demonstrate in reports checkpoint metastatic These over Further in is suggest National months the refractory that in immune that of the Cancer patients Also, this tumors by objective is the evidence to the with this the an months median VERSATILE-XXX a the Historically, XX treat of XX%. in combination patients Cancer this optimal Institute of inhibitor inhibitors and triple of effect inhibitors objective after in rate in that a checkpoint this objective to induced of overall may with the received of a with checkpoint those the response effectively rate In chemotherapy checkpoint population XX appear in receive the T data with neck XX%
As perform work the the us promising you to combinations and can to centers have some indications we which enable of better, world of respected see combinations the progress in select may allow registrational indications trials. in broad into this to table, to in quickly to us more collaborated studies the the most understand and to range cancer various with most rapidly strategically
to may be data date, look is head to suitable fact continue patients combination dual PDSXXXX three results in for from we HPVXX to patients safety encouraged the many efficacy Phase of to data safety date, the priority XXX reported we as XXXX determine checkpoint and feasible. metastatic generated that neck immunological the in to example, to inhibitor As the as X trial and the The And and from be commercialization allowed possible PDSXXXX to trials. to we rapidly by us of and ahead over VERSATILE-XXX efficacy potential consistent XX cancer. that PDSXXXX. are data To in demonstrate indications as and KEYTRUDA as our most related clinical key over recurrent beyond, address advance and and has have naive
a ability in tumor T-cells to using inhibitor that immune refractory generating advanced combination more attacking However, tumor the such the data plus further suggest makes IL-XX combination this patient the in to this more in disease, platform in suppression, while disease, evaluate broadly National advanced preferred immune diverse trial. overcome Institute in triple checkpoint population generated registrational our the Cancer by
met speed We by you KEYTRUDA FDA to program been the a key FDA quarter meeting inhibitor trial lead The triple guidance on end progress the PDS and encouraged combination the begun development aware, biologics a discuss National to Institute combination will potential NCI, the PDSXXXX. combination will elements that X the for on the we designation refractory this are ahead in the has triple The in with of PDSXXXX timeline Institute our the Similarly of remain on the upcoming and the completing end that of in by FDA. granted that holidays. PDS FDA and hopeful Biotech to Track our before Cancer As this FDA trial recruitment of the received of and a data development progressing the license that FDA this Institute the and guidance the end, quarter are year, successful third the has on process meeting, potential next has by focus the assets provided the We schedule, trial. led year. with the into to into meet checkpoint of registrational clinical To combination. Biotech from population. the our depending We steps with Fast Cancer Biotech both attention date the with the Phase application up has to preparing initial decided CMC announced based trial National National towards in one submission approximately support registrational quarter XXXX. FDA the the announced to Cancer PDS
FDA over conference I into take if ahead initiation trial registrational go As precedence did would PDSXXXX. the we the it VERSATILE-XXX trial, of get call, our in progress to last a the from alluded to
stated. to the of result, would XXXX. moved as for us and we a of to preparation As National first PDSXXXX have like product through now SITC Lauren? manufacturing take presented her at all the date half Anderson clinical MD Lauren, is the progressing call for at to Institute. the previously collaborators over recently IND the Clinical to the the data Cancer turn by Center, I Cancer
